welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Cancer Prevention Pharmaceuticals Completes Target Enrollment in Pivotal Phase 3 Clinical Trial Evaluating CPP-1X/sulindac in Patients with Familial Adenomatous Polyposis
Cancer Prevention Pharmaceuticals, Inc. (CPP), a private biotech company developing novel therapeutics to prevent cancer and other diseases, announced today that target enrollment has been achieved for the company’s pivotal Phase 3 clinical trial, CPP FAP-310, evaluating CPP-1X/sulindac in adults with familial adenomatous polyposis (FAP).
expertly curated content related to this topic
- A Study of Guselkumab in Participants With Familial Adenomatous PolyposisThe purpose of this study is to determin...
- Food Fit for a J-Pouchhttps://www.youtube.com/watch?v=RxiYAWkx...
- Eicosapentaenoic Acid Reduces Rectal Polyp Number and Size in Familial Adenomatous PolyposisOBJECTIVE : The omega-3 polyunsaturated ...
- PTSD common in patients with familial adenomatous polyposisPosttraumatic stress disorder is common ...
- Genetics, Inheritance and Strategies for Prevention in Populations at High Risk of Colorectal Cancer (CRC)Hereditary forms of colorectal cancer ac...
- Familial Adenomatous Polyposis and Desmoid TumorsFamilial adenomatous polyposis (FAP) is ...
- Prospective Randomized Study of Sulindac versus Calcium and Calciferol for Upper Gastrointestinal Polyps in Familial...Eighteen patients with familial adenomat...
English
Portuguese